Key Details
Price
$0.41Annual EPS
-$12.97Annual ROE
-785.27%Beta
0.48Events Calendar
Next earnings date:
Mar 26, 2025Recent quarterly earnings:
Nov 14, 2024Recent annual earnings:
Mar 26, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Mar 01, 2024Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced results from a minipig Dose Range Finding (“DRF”) study for Probudur. Probudur is the company's long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate.
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today the closing of its public offering of $5.0 million of shares of the Company's common stock, par value $0.00001 per share, and pre-funded warrants to purchase shares of common stock at a public offering price of $0.50 per share (minus $0.00001 per pr.
Virpax Pharmaceuticals (NASDAQ: VRPX ) stock is rocketing higher on Wednesday after the preclinical-stage pharmaceutical company announced positive results from a swine model pilot study. Virpax Pharmaceuticals has released results from its swine model study of Probudur.
Wednesday, Virpax Pharmaceuticals Inc VRPX released results for a Swine Model pilot study for Probudur, Virpax's long-acting liposomal bupivacaine formulation injected at a wound site to provide immediate and extended pain relief.
Virpax Pharmaceuticals (NASDAQ: VRPX ) stock is heading higher on Monday after the preclinical-stage pharmaceutical company secured a new $2.5 million loan. Virpax Pharmaceuticals says that this funding comes from an institutional investor.
FAQ
- What is the primary business of Virpax Pharmaceuticals?
- What is the ticker symbol for Virpax Pharmaceuticals?
- Does Virpax Pharmaceuticals pay dividends?
- What sector is Virpax Pharmaceuticals in?
- What industry is Virpax Pharmaceuticals in?
- What country is Virpax Pharmaceuticals based in?
- When did Virpax Pharmaceuticals go public?
- Is Virpax Pharmaceuticals in the S&P 500?
- Is Virpax Pharmaceuticals in the NASDAQ 100?
- Is Virpax Pharmaceuticals in the Dow Jones?
- When was Virpax Pharmaceuticals's last earnings report?
- When does Virpax Pharmaceuticals report earnings?
- Should I buy Virpax Pharmaceuticals stock now?